CLEVELAND/PRNewswire/ — ViewRay™ Incorporated, a
privately held medical device company, has received U.S. FDA 510(k) premarket
notification clearance for its MRI-guided radiation therapy system. The ViewRay
system features a unique combination of radiotherapy delivery and simultaneous
magnetic resonance imaging (MRI) for the treatment of cancer. ViewRay’s
treatment planning and delivery software received 510(k) premarket notification
clearance in 2011.
“FDA clearance of our integrated system is a major
milestone in the development of our technology,” said ViewRay President
and CEO Gregory M. Ayers, MD, PhD. “It has already been an exciting year
for ViewRay, with an additional round of funding and the installation of our
first research systems at major U.S.
medical centers. Early clinical imaging studies have verified the quality of
the system’s MR images, and now we’re looking forward to clinical
applications.” The ViewRay system provides continuous soft-tissue imaging
during treatment so that clinicians can see and record precisely where
radiation therapy is being delivered, as it’s being delivered.
ViewRay’s patented cancer treatment technology was invented
by company founder James F. Dempsey, PhD, while he was a member of the
radiation oncology faculty at the University
of Florida. “ViewRay
began with the idea that we need to see what exactly we’re doing when we treat
cancer patients with radiation therapy,” said Dempsey, now ViewRay’s chief
scientific officer. “Thanks to our clear vision, an outstanding
engineering team, and dedicated leadership, we’re now able to bring that idea
into the clinic, where it can help cancer patients.”
ViewRay recently closed the final tranche of a $45 million
round of Series C venture capital financing intended to advance the ViewRay
system toward commercialization. The first ViewRay system is installed at the Siteman Cancer Center
at Barnes?Jewish Hospital and Washington University School of Medicine, where
early imaging studies have taken place. Additional ViewRay partners include the
UCLA Jonsson Comprehensive
and the University of Wisconsin Carbone Cancer Center, where a ViewRay system
is currently being installed.
ViewRay Incorporated of Cleveland,
Ohio, is a privately held medical
device company developing advanced radiation therapy technology for the
treatment of cancer. The ViewRay system provides continuous soft-tissue imaging
during treatment, using MRI-guided radiotherapy, so that clinicians are able to
see where the actual radiation dose is being delivered and adapt to changes in
the patient’s anatomy. For more information, visit http://www.viewray.com.